WEHI researchers have made a huge leap forward in the fight against Parkinson's disease, solving a decades-long mystery that paves the way for development of new drugs to treat the condition.

Global Parkinson’s disease cases are projected to more than double to 25.2 million by 2050, driven largely by aging ...

Researchers say structure reveals many new ways to change PINK1, essentially switching it on, which will be "life-changing" for people with Parkinson’s disease.

The medications, known as dopamine agonists, are designed to mimic dopamine—the brain chemical that controls movement and also plays a major role in how we experience pleasure.

I just can’t get enough of it,” Bill Easterly told The Post. “When I play pingpong, I just feel my brain come alive.” ...

A new study reveals that men are over twice as likely to develop Parkinson's disease compared to women, due to aggressive T ...

Patients prescribed dopamine agonists, a widely used class of drugs for conditions such as Parkinson's disease and restless ...

Patients who were prescribed drugs for restless legs syndrome (RLS) have said doctors did not warn them about significant ...

What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

Three research teams have been selected as recipients of the 2024 Blavatnik Therapeutics Challenge Awards, an annual awards ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...